Bolden Therapeutics is a biotechnology company developing first-in-class therapeutics to treat central nervous system diseases such as Alzheimer’s and ischemic stroke. The company’s scientific founders have identified a key molecular pathway to stimulate neural stem cells to promote the birth of new neurons (neurogenesis) in the adult brain. In a proprietary mouse model Bolden has established a proof-of-concept of this approach to increase neurogenesis and enhance hippocampal-dependent memory. The company is actively developing antisense oligonucleotide and monoclonal antibody therapeutics to modulate this pathway.
Bolden Therapeutics Address
225 Dyer Street Providence, RI
Bolden Therapeutics Email
Past Companies
Bolden TherapeuticsCo-Founder and CEO
The Warren Alpert Medical School of Brown UniversityMD Candidate
Brown UniversityGraduate Research Assistant - Fallon Lab, Department of Neuroscience